CRP and myeloid sarcoma: After evaluating the combined effect of CRP and MS, it was found that both no MS plus elevated CRP (HR, 1.22; 95%CI, 1.02–1.47) and MS plus elevated CRP (HR, 1.29; 95%CI, 1.05–1.58) participants had increased HNC risk compared to those without MS and CRP<1.00 mg/dL.